These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 11522237)
21. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. Kalland T; Belfrage H; Bhiladvala P; Hedlund G J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566 [TBL] [Abstract][Full Text] [Related]
22. In vivo purging and relapse prevention following ASCT. Gisselbrecht C Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S5-9. PubMed ID: 11840154 [TBL] [Abstract][Full Text] [Related]
23. Lymphokine-activated killer (LAK) cell purging of bone marrow. Cramer DV; Long GS Prog Clin Biol Res; 1990; 333():125-35; discussion 136-7. PubMed ID: 2308977 [TBL] [Abstract][Full Text] [Related]
24. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts. Klingemann HG; Deal H; Reid D; Eaves CJ Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650 [TBL] [Abstract][Full Text] [Related]
25. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy. Talmadge JE Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168 [TBL] [Abstract][Full Text] [Related]
26. Purging of peripheral blood progenitor cell autografts and treatment of minimal residual disease. Brugger W; Scheding S; Bock T; Ziegler B; Kanz L Stem Cells; 1997; 15 Suppl 1():159-65. PubMed ID: 9368336 [TBL] [Abstract][Full Text] [Related]
27. Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma. Pettengell R Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S1-4. PubMed ID: 11840153 [TBL] [Abstract][Full Text] [Related]
29. Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets. Cesano A; Pierson G; Visonneau S; Migliaccio AR; Santoli D Blood; 1996 Jan; 87(1):393-403. PubMed ID: 8547668 [TBL] [Abstract][Full Text] [Related]
30. The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Van Besien K Blood Rev; 2006 Sep; 20(5):235-44. PubMed ID: 16513231 [TBL] [Abstract][Full Text] [Related]
31. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Koehl U; Esser R; Zimmermann S; Tonn T; Kotchetkov R; Bartling T; Sörensen J; Grüttner HP; Bader P; Seifried E; Martin H; Lang P; Passweg JR; Klingebiel T; Schwabe D Klin Padiatr; 2005; 217(6):345-50. PubMed ID: 16307421 [TBL] [Abstract][Full Text] [Related]
32. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging. Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504 [TBL] [Abstract][Full Text] [Related]
33. Application of hypothermia to autologous stem cell purging. Miyagi K; Yamazaki T; Tsujino I; Takahashi N; Koya Y; Masutani M; Sawada U; Horie T Cryobiology; 2001 May; 42(3):190-5. PubMed ID: 11578118 [TBL] [Abstract][Full Text] [Related]
34. Tumor cell contamination in re-infused stem cell autografts: does it have clinical significance? Shimoni A; Körbling M Crit Rev Oncol Hematol; 2002 Feb; 41(2):241-50. PubMed ID: 11856599 [TBL] [Abstract][Full Text] [Related]
35. Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production. Klingemann HG; Neerunjun J; Schwulera U; Ziltener HJ Leukemia; 1993 Sep; 7(9):1389-93. PubMed ID: 8371589 [TBL] [Abstract][Full Text] [Related]
36. Purging marrow or peripheral blood stem cells for autografting. Hammert LC; Ball ED Curr Opin Hematol; 1997 Nov; 4(6):423-8. PubMed ID: 9359000 [TBL] [Abstract][Full Text] [Related]
37. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement. Morishima Y; Miyamura K; Kojima S; Ueda R; Morishita Y; Sao H; Tanimoto M; Ohno R; Sobue R; Hirano M Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550 [TBL] [Abstract][Full Text] [Related]
38. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine. Balzarotti M; Grisanti S; Granzow K; Saladini A; Sala A; Nozza A; Molteni A; Passamonti F; Carlo-Stella C; Santoro A; Siena S Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263 [TBL] [Abstract][Full Text] [Related]
39. Graft purging in autologous bone marrow transplantation: a promise not quite fulfilled. Alvarnas JC; Forman SJ Oncology (Williston Park); 2004 Jun; 18(7):867-76; discussion 876-8, 881, 884. PubMed ID: 15255171 [TBL] [Abstract][Full Text] [Related]
40. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients. Visani G; Lemoli RM; Isidori A; Piccaluga PP; Martinelli G; Malagola M; Gugliotta L; Bonini A; Bonifazi F; Motta MR; Rizzi S; Castellani S; Tura S Bone Marrow Transplant; 2001 Apr; 27(8):829-35. PubMed ID: 11477440 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]